CERo Therapeutics Holdings, Inc. Common Stock (CERO NASDAQ) stock market data APIs
$5.4739
0.16(2.9%)
as of September 17, 2025
Try our APIs with
free plan!
CERo Therapeutics Holdings, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Prev. Close
5.4739
Open
5.637
High
5.7445
Low
5.4581
52 wk Range
4.27-896
Market Cap
6 835 K
Shares Outstanding
1 205 K
EPS
-61.71
Beta
0.497
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CERo Therapeutics Holdings, Inc. Common Stock data using free add-ons & libraries
Get CERo Therapeutics Holdings, Inc. Common Stock Fundamental Data
CERo Therapeutics Holdings, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -16 679 652
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get CERo Therapeutics Holdings, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-22
- EPS/Forecast: -6.21
Get CERo Therapeutics Holdings, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CERo Therapeutics Holdings, Inc. Common Stock News
New
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., ...
The trading volume of these stocks is deviating from the norm in today's session.
Let's have a look at the stocks with an unusual volume in today's session. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT HOUR [https://www.chartmill.com/stock/quote/HOUR/pr...
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLO...
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
